Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MXCT NYSE:RENX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMXCTMaxCyte$1.45-2.0%$1.75$1.26▼$5.20$154.58M1.2788,474 shs476,332 shsRENXRelx$21.19$0.00$20.06▼$23.30N/AN/A100,590 shs547,934 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMXCTMaxCyte0.00%+2.84%+6.62%-35.27%-64.02%RENXRelx0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMXCTMaxCyte$1.45-2.0%$1.75$1.26▼$5.20$154.58M1.2788,474 shs476,332 shsRENXRelx$21.19$0.00$20.06▼$23.30N/AN/A100,590 shs547,934 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMXCTMaxCyte0.00%+2.84%+6.62%-35.27%-64.02%RENXRelx0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMXCTMaxCyte 2.50Moderate Buy$7.00382.76% UpsideRENXRelx 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest YGEN, OSL, MXCT, and RENX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025MXCTMaxCyteBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral8/7/2025MXCTMaxCyteWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform7/22/2025MXCTMaxCyteStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$6.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMXCTMaxCyte$38.63M4.00N/AN/A$1.95 per share0.74RENXRelxN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMXCTMaxCyte-$41.06M-$0.43N/AN/AN/A-125.22%-22.12%-19.10%11/5/2025 (Estimated)RENXRelxN/A$1.2217.37∞N/AN/AN/AN/AN/ALatest YGEN, OSL, MXCT, and RENX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025MXCTMaxCyte-$0.10-$0.12-$0.02-$0.12$9.57 million$8.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMXCTMaxCyteN/AN/AN/AN/AN/ARENXRelx$0.281.32%N/A22.95%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMXCTMaxCyteN/A12.4011.71RENXRelxN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMXCTMaxCyte68.81%RENXRelx1.37%Insider OwnershipCompanyInsider OwnershipMXCTMaxCyte3.30%RENXRelxN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMXCTMaxCyte80106.61 million103.09 millionOptionableRENXRelxN/AN/AN/ANot OptionableYGEN, OSL, MXCT, and RENX HeadlinesRecent News About These CompaniesReba McEntire Reveals Engagement Ring From Rex Linn at Emmys 20251 hour ago | eonline.comEWho is Rex Linn? Net worth and more as Reba McEntire reveals she’s engaged1 hour ago | soapcentral.comSReba McEntire & Rex Linn Confirm Major Relationship News During Emmys Red Carpet1 hour ago | aol.comAReba McEntire Has Date Night With Rex Linn at Emmy Awards 2025 1 Month After Brandon Blackstock’s Death1 hour ago | yahoo.comReba McEntire and Boyfriend Rex Linn Are Engaged After 5 Years of Dating1 hour ago | yahoo.comReba McEntire and Rex Linn Announce Engagement at 2025 Primetime Emmys5 hours ago | msn.comReba McEntire + Rex Linn Engaged After Nearly 30 Years of Friendship5 hours ago | msn.comReba McEntire reveals she’s engaged to actor Rex Linn during Emmys Interview5 hours ago | soapcentral.comSReba McEntire Confirms Engagement to Rex Linn During 2025 Emmys Red Carpet Interview5 hours ago | aol.comAReba McEntire’s Fiance: Meet Rex Linn & Learn More About Her Past Marriages5 hours ago | msn.comReba McEntire confirms engagement to Rex Linn during Emmys date night5 hours ago | usatoday.comRex Linn Reveals Reba McEntire's Late-Night Habit During Emmys 2025 Date NightSeptember 14 at 8:58 PM | msn.comReba McEntire and Boyfriend Rex Linn Hold Hands on Emmys Red Carpet — See the PhotosSeptember 14 at 8:58 PM | popculture.comPReba McEntire & Rex Linn Are Engaged!September 14 at 8:58 PM | msn.comEmmys 2025: Rex Linn Shares Reba McEntire's Late-Night HabitSeptember 14 at 8:58 PM | yahoo.comReba McEntire and Rex Linn Confirm Engagement at Emmys 2025September 14 at 8:58 PM | msn.comReba McEntire and Rex Linn Are Engaged After 5 Years of DatingSeptember 14 at 8:58 PM | msn.comRex Ryan Rips ‘Nerd Boy’ Coach as Dolphins Face Must-Win Week 2September 13 at 3:51 PM | msn.comREX-Osprey Solana Staking ETF’s AUM Hits New High Amid SOL RallySeptember 12 at 3:45 PM | coingape.comCHow to buy REX-Osprey DOJE (Dogecoin, XRP, Trump, Bonk ETF) sharesSeptember 12 at 3:45 PM | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeYGEN, OSL, MXCT, and RENX Company DescriptionsMaxCyte NASDAQ:MXCT$1.45 -0.03 (-2.03%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.50 +0.05 (+3.10%) As of 04:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.Relx NYSE:RENXRELX NV, through its interest in RELX Group plc, provides information and analytics for professional and business customers across industries worldwide. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment offers information and analytics to institutions and professionals. The Risk & Business Analytics segment provides solutions and decision tools that combine public and industry specific content with technology and analytics to evaluate and predict risk, as well as enhance operational efficiency. The Legal segment offers legal, regulatory, and business information and analytics. The Exhibitions segment is involved in the events business. The company was formerly known as Reed Elsevier NV and changed its name to RELX NV in June 2015. RELX NV was incorporated in 1880 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
